Jump to content

C. Glenn Begley: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Adding short description: "Australian hematologist and oncologist" (Shortdesc helper)
Line 1: Line 1:
{{short description|Australian hematologist and oncologist}}
'''C. Glenn Begley''' is a hematologist and oncologist who serves as the CEO of BioCurate, an [[Australia]]-based joint venture between the [[University of Melbourne]] and [[Monash University]] that was launched in 2016.<ref name=bc>{{Cite web |url=http://biocurate.com/news/2017/4/30/ceo-appointed |title=CEO Appointed |date=2017-04-30 |website=BioCurate |language=en-US |access-date=2018-04-25}}</ref> Previously, he worked at the [[California]]-based biotech company Akriveia Therapeutics as their Chief Scientific Officer. His other previous positions include global head of [[hematology]] and [[oncology]] research at [[Amgen]], senior vice president and chief scientific officer at TetraLogic Pharmaceuticals, and executive director of the [[Western Australian Institute of Medical Research]]. He studied [[medicine]] at the University of Melbourne.<ref name=bc/> He is known for a study he co-authored in 2012 in which he found that only 6 out of 53 (11%) of landmark preclinical studies of cancer drugs could be reproduced.<ref>{{Cite journal |last=Begley |first=C. Glenn |last2=Ellis |first2=Lee M. |date=March 2012 |title=Drug development: Raise standards for preclinical cancer research |url=http://www.nature.com/articles/483531a |journal=Nature |language=En |volume=483 |issue=7391 |pages=531–533 |doi=10.1038/483531a |issn=0028-0836}}</ref><ref>{{Cite web |url=https://www.npr.org/sections/health-shots/2014/04/08/298335701/how-mouse-studies-lead-medical-research-down-dead-ends |title=How Mouse Studies Lead Medical Research Down Dead Ends |date=2014-04-08 |website=NPR |language=en |access-date=2018-04-25}}</ref><ref>{{Cite web |url=http://www.slate.com/articles/health_and_science/science/2012/08/reproducing_scientific_studies_a_good_housekeeping_seal_of_approval_.html |title=Good Scientist! You Get a Badge. |last=Zimmer |first=Carl |date=2012-08-14 |website=Slate |language=en-US |access-date=2018-04-25}}</ref><ref>{{Cite web |url=https://www.reuters.com/article/us-science-cancer/in-cancer-science-many-discoveries-dont-hold-up-idUSBRE82R12P20120328 |title=In cancer science, many "discoveries" don't hold up |last=Begley |first=Sharon |date=2012-03-28 |website=Reuters |language=en-US |access-date=2018-04-25}}</ref> He was elected to the [[American Society for Clinical Investigation]] in 2000.<ref>{{Cite web |url=https://www.the-asci.org/controllers/asci/AsciProfileController.php?pid=500163 |title=C Glenn Begley |website=American Society for Clinical Investigation}}</ref> Begley was elected Fellow of the [[Australian Academy of Health and Medical Sciences]] in 2015.<ref>{{Cite web|url=http://www.aahms.org/fellowship/|title=Fellowship {{!}} AAHMS – Australian Academy of Health and Medical Sciences|website=www.aahms.org|language=en-AU|access-date=2018-06-25}}</ref>
'''C. Glenn Begley''' is a hematologist and oncologist who serves as the CEO of BioCurate, an [[Australia]]-based joint venture between the [[University of Melbourne]] and [[Monash University]] that was launched in 2016.<ref name=bc>{{Cite web |url=http://biocurate.com/news/2017/4/30/ceo-appointed |title=CEO Appointed |date=2017-04-30 |website=BioCurate |language=en-US |access-date=2018-04-25}}</ref> Previously, he worked at the [[California]]-based biotech company Akriveia Therapeutics as their Chief Scientific Officer. His other previous positions include global head of [[hematology]] and [[oncology]] research at [[Amgen]], senior vice president and chief scientific officer at TetraLogic Pharmaceuticals, and executive director of the [[Western Australian Institute of Medical Research]]. He studied [[medicine]] at the University of Melbourne.<ref name=bc/> He is known for a study he co-authored in 2012 in which he found that only 6 out of 53 (11%) of landmark preclinical studies of cancer drugs could be reproduced.<ref>{{Cite journal |last=Begley |first=C. Glenn |last2=Ellis |first2=Lee M. |date=March 2012 |title=Drug development: Raise standards for preclinical cancer research |url=http://www.nature.com/articles/483531a |journal=Nature |language=En |volume=483 |issue=7391 |pages=531–533 |doi=10.1038/483531a |issn=0028-0836}}</ref><ref>{{Cite web |url=https://www.npr.org/sections/health-shots/2014/04/08/298335701/how-mouse-studies-lead-medical-research-down-dead-ends |title=How Mouse Studies Lead Medical Research Down Dead Ends |date=2014-04-08 |website=NPR |language=en |access-date=2018-04-25}}</ref><ref>{{Cite web |url=http://www.slate.com/articles/health_and_science/science/2012/08/reproducing_scientific_studies_a_good_housekeeping_seal_of_approval_.html |title=Good Scientist! You Get a Badge. |last=Zimmer |first=Carl |date=2012-08-14 |website=Slate |language=en-US |access-date=2018-04-25}}</ref><ref>{{Cite web |url=https://www.reuters.com/article/us-science-cancer/in-cancer-science-many-discoveries-dont-hold-up-idUSBRE82R12P20120328 |title=In cancer science, many "discoveries" don't hold up |last=Begley |first=Sharon |date=2012-03-28 |website=Reuters |language=en-US |access-date=2018-04-25}}</ref> He was elected to the [[American Society for Clinical Investigation]] in 2000.<ref>{{Cite web |url=https://www.the-asci.org/controllers/asci/AsciProfileController.php?pid=500163 |title=C Glenn Begley |website=American Society for Clinical Investigation}}</ref> Begley was elected Fellow of the [[Australian Academy of Health and Medical Sciences]] in 2015.<ref>{{Cite web|url=http://www.aahms.org/fellowship/|title=Fellowship {{!}} AAHMS – Australian Academy of Health and Medical Sciences|website=www.aahms.org|language=en-AU|access-date=2018-06-25}}</ref>


Revision as of 13:16, 7 May 2019

C. Glenn Begley is a hematologist and oncologist who serves as the CEO of BioCurate, an Australia-based joint venture between the University of Melbourne and Monash University that was launched in 2016.[1] Previously, he worked at the California-based biotech company Akriveia Therapeutics as their Chief Scientific Officer. His other previous positions include global head of hematology and oncology research at Amgen, senior vice president and chief scientific officer at TetraLogic Pharmaceuticals, and executive director of the Western Australian Institute of Medical Research. He studied medicine at the University of Melbourne.[1] He is known for a study he co-authored in 2012 in which he found that only 6 out of 53 (11%) of landmark preclinical studies of cancer drugs could be reproduced.[2][3][4][5] He was elected to the American Society for Clinical Investigation in 2000.[6] Begley was elected Fellow of the Australian Academy of Health and Medical Sciences in 2015.[7]

References

  1. ^ a b "CEO Appointed". BioCurate. 2017-04-30. Retrieved 2018-04-25.
  2. ^ Begley, C. Glenn; Ellis, Lee M. (March 2012). "Drug development: Raise standards for preclinical cancer research". Nature. 483 (7391): 531–533. doi:10.1038/483531a. ISSN 0028-0836.
  3. ^ "How Mouse Studies Lead Medical Research Down Dead Ends". NPR. 2014-04-08. Retrieved 2018-04-25.
  4. ^ Zimmer, Carl (2012-08-14). "Good Scientist! You Get a Badge". Slate. Retrieved 2018-04-25.
  5. ^ Begley, Sharon (2012-03-28). "In cancer science, many "discoveries" don't hold up". Reuters. Retrieved 2018-04-25.
  6. ^ "C Glenn Begley". American Society for Clinical Investigation.
  7. ^ "Fellowship | AAHMS – Australian Academy of Health and Medical Sciences". www.aahms.org. Retrieved 2018-06-25.


Stub icon 1 Stub icon 2

This biographical article related to medicine in Australia is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=C._Glenn_Begley&oldid=895945518"